Determination of plasma homocysteine: recommendations for test requesting. High plasma homocysteine concentrations can be caused by various factors, including low blood concentrations of B-complex vitamins. Hyperhomocysteinemia is widely believed to be associated with an increased risk of atherosclerotic disease; recent emerging evidence made, however, doubtful its role as cardiovascular risk factor. The aim of this document was to examine the appropriateness of homocysteine requesting in our clinical setting. Clinical guidelines, meta-analyses and systematic reviews were used as source of high level evidence. During the last two decades, the role of hyperhomocysteinemia was examined in a number of clinical conditions; however, the analysis of available data made us clear that determination of plasma homocysteine has only limited clinical role. Test requesting results to be appropriate only in case of suspected homocystinuria (an inherited disorder of the metabolism of the amino acid methionine), in patients with previous venous or arterial thromboembolism and in patients with severe (>100 µmol/L) [and possibly moderate (>30 µmol/L)] hyperhomocysteinemia treated with B-complex vitamins. Determination of plasma homocysteine is not recommended as a primary prevention tool for cardiovascular disease in the general population.

Determinazione dell'omocisteina plasmatica: Indicazioni per la richiesta = Determination of plasma homocysteine: Recommendations for test requesting / D. Szőke, A. Dolci, U. Russo, M. Panteghini. - In: BIOCHIMICA CLINICA. - ISSN 0393-0564. - 38:3(2014 Jun), pp. 234-237.

Determinazione dell'omocisteina plasmatica: Indicazioni per la richiesta = Determination of plasma homocysteine: Recommendations for test requesting

A. Dolci
Secondo
;
M. Panteghini
Ultimo
2014

Abstract

Determination of plasma homocysteine: recommendations for test requesting. High plasma homocysteine concentrations can be caused by various factors, including low blood concentrations of B-complex vitamins. Hyperhomocysteinemia is widely believed to be associated with an increased risk of atherosclerotic disease; recent emerging evidence made, however, doubtful its role as cardiovascular risk factor. The aim of this document was to examine the appropriateness of homocysteine requesting in our clinical setting. Clinical guidelines, meta-analyses and systematic reviews were used as source of high level evidence. During the last two decades, the role of hyperhomocysteinemia was examined in a number of clinical conditions; however, the analysis of available data made us clear that determination of plasma homocysteine has only limited clinical role. Test requesting results to be appropriate only in case of suspected homocystinuria (an inherited disorder of the metabolism of the amino acid methionine), in patients with previous venous or arterial thromboembolism and in patients with severe (>100 µmol/L) [and possibly moderate (>30 µmol/L)] hyperhomocysteinemia treated with B-complex vitamins. Determination of plasma homocysteine is not recommended as a primary prevention tool for cardiovascular disease in the general population.
Settore BIO/12 - Biochimica Clinica e Biologia Molecolare Clinica
giu-2014
http://www.sibioc.it/bc/numero/bcnum/146
Article (author)
File in questo prodotto:
File Dimensione Formato  
2014 BC Dolci et al. Omocisteina indicazioni per la richiesta.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 59.89 kB
Formato Adobe PDF
59.89 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/236386
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? ND
social impact